{"id":70664,"date":"2026-05-12T08:56:17","date_gmt":"2026-05-12T08:56:17","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70664"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mots-c","status":"publish","type":"product","link":"https:\/\/medsbase.com\/de\/product\/mots-c\/","title":{"rendered":"MOTS-c"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Kurze Antwort \u2014 Was ist MOTS-c?<\/h3>\n<p style=\"margin: 0;\"><strong>MOTS-c<\/strong> (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondrially-encoded signaling peptide first identified in 2015. In published preclinical studies it acts as an exercise-mimetic and metabolic regulator by activating the AMPK pathway, restoring insulin sensitivity, and modulating nuclear gene expression in response to mitochondrial stress. Supplied in 10\u00a0mg to 40\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Was Sie bei MedsBase erhalten:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/de\/reviews\/\">Kundenbewertungen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jede Bestellung ist durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> abgedeckt \u2014 wenn Ihr Paket nicht innerhalb von 20 Werktagen ankommt, versenden wir es erneut.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Spezifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1627580-64-6<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekularformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2174.62 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR, 16 Aminos\u00e4uren; kodiert im mitochondrialen 12S-rRNA-Gen)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat (wei\u00df bis leicht gelblich)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Reinheit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-best\u00e4tigt, COA auf Anfrage)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Lagerung<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat: 2\u20138 \u00b0C (K\u00fchlschrank) f\u00fcr Arbeitsvorrat; \u221220 \u00b0C zur Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituiert: 2\u20138 \u00b0C, innerhalb von ~30 Tagen verwenden. Vor Licht sch\u00fctzen. Die rekonstituierte L\u00f6sung nicht einfrieren und auftauen.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slichkeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatisches Wasser (empfohlen) oder steriles Wasser f\u00fcr k\u00fcrzere Anwendungszeitr\u00e4ume<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Was ist MOTS-c?<\/h2>\n<p><strong>MOTS-c<\/strong> (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) ist ein 16-Aminos\u00e4uren-Peptid, das erstmals von Lee et al. in <em>Cell Metabolism<\/em> (2015) as a member of the newly recognised class of mitochondrially-derived peptides (MDPs). Unlike every other peptide in the studies catalog \u2014 which are encoded by nuclear DNA and synthesised in the cytoplasm \u2014 MOTS-c is encoded within the mitochondrial 12S rRNA gene and translated by mitochondrial ribosomes. This unusual biological origin makes it a direct intracellular signal of mitochondrial state, and the most-cited member of a peptide class that includes humanin and the SHLP family. The peptide sequence is MRWQEMGYIFYPRKLR, molecular weight approximately 2,175\u00a0Da, empirical formula C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub>. Endogenes MOTS-c verlagert sich unter metabolischem und oxidativem Stress von den Mitochondrien in den Zellkern, wo es ein Fols\u00e4urezyklus-\/Methioninstoffwechsel-Genprogramm reguliert \u2013 ein Mechanismus, der unter kernkodierten Peptiden ohne Parallele ist. MOTS-c wird als hochreines lyophilisiertes Pulver zur Rekonstitution mit bakterienstatischem Wasser geliefert und ist <strong>for clinical studies use only<\/strong>. For related metabolic and longevity peptides, see our full <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">Peptid-Katalog<\/a>. <\/p>\n<h2>Wirkmechanismus \u2013 AMPK, Glukosestoffwechsel und nukle\u00e4re Translokation<\/h2>\n<p>Was MOTS-c von \u00e4lteren metabolischen Peptiden unterscheidet, ist sein <strong>trimodaler Wirkmechanismus<\/strong> that spans the mitochondrion, the cytoplasm, and the nucleus \u2014 each contributing to the observed metabolic phenotype in published studies:<\/p>\n<ul>\n<li><strong>AMPK-Pfad-Aktivierung<\/strong> \u2013 MOTS-c aktiviert die AMP-aktivierte Proteinkinase (AMPK), den zellul\u00e4ren Hauptenergiesensor, durch Erh\u00f6hung des intrazellul\u00e4ren AMP:ATP-Verh\u00e4ltnisses und \u00fcber einen fols\u00e4urezyklusabh\u00e4ngigen Mechanismus. Die AMPK-Aktivierung verschiebt den zellul\u00e4ren Stoffwechsel in Richtung Katabolismus: erh\u00f6hte Glukoseaufnahme via GLUT4-Translokation, Fetts\u00e4ureoxidation, mitochondriale Biogenese durch PGC-1\u03b1 und Autophagie. Dies ist derselbe Pfad, der durch Metformin und Bewegung angesteuert wird, was MOTS-c in der ver\u00f6ffentlichten Literatur die Bezeichnung \u201cExercise-mimetic Peptide\u201d eingebracht hat.<\/li>\n<li><strong>Insulinsensitivit\u00e4t und Glukoseverwertung<\/strong> \u2014 In high-fat-diet rodent models, MOTS-c administration restores insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. The effect is independent of body-weight change in some studies designs, suggesting a direct insulin-sensitising mechanism rather than secondary to weight loss. MOTS-c-treated obese mice show normalised oral glucose tolerance and improved euglycaemic-clamp parameters in published studies.<\/li>\n<li><strong>Nukleare Translokation und adaptive Genexpression<\/strong> \u2014 Unter metabolischem oder oxidativem Stress translokiert MOTS-c von den Mitochondrien in den Zellkern, wo es ein Transkriptionsprogramm mitreguliert, das auf die antioxidative Reaktion (NRF2), den Folat-Methionin-Zyklus und adaptive Stoffwechselgene ausgerichtet ist. Diese mitochondriale-nukleare retrograde Signal\u00fcbertragung ist eines der ersten Beispiele f\u00fcr intrazellul\u00e4re Kommunikation zwischen Kompartimenten auf Peptidebene und bildet die Grundlage f\u00fcr die breiteren Wirkungen von MOTS-c jenseits der direkten AMPK-Aktivierung.<\/li>\n<\/ul>\n<p>The biological appeal of MOTS-c in metabolic support is the convergence of these three mechanisms onto pathways already known to mediate the benefits of exercise and caloric restriction. Because endogenous MOTS-c declines markedly with age in human serum (~50% reduction across adult lifespan in published cohorts), the peptide has become a frequent target in aging and longevity studies as well as in metabolic syndrome. <\/p>\n<h2>Published Evidence<\/h2>\n<p>MOTS-c is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Metabolic syndrome and obesity studies<\/strong> \u2014 insulin sensitivity, glucose tolerance, body composition in high-fat-diet rodent models; benchmark peptide for AMPK-axis intervention studies (Lee et al., Cell Metabolism 2015; Reynolds et al., Front Physiol 2021)<\/li>\n<li><strong>Pr\u00e4klinische Modelle von Typ-2-Diabetes<\/strong> \u2014 db\/db, ZDF und Streptozotocin-induzierte Diabetesmodelle; Auswirkungen auf die hepatische Insulinsensitivit\u00e4t, Betazellfunktion und HbA1c-Surrogate<\/li>\n<li><strong>Trainingskapazit\u00e4t und mitochondriale Biogenese<\/strong> \u2014 Laufbandausdauer, VO<sub>2<\/sub>max surrogates, PGC-1\u03b1 expression, mitochondrial DNA copy number in skeletal muscle studies<\/li>\n<li><strong>Aging and longevity studies<\/strong> \u2014 lifespan extension models, age-related insulin resistance, sarcopenia; MOTS-c serum levels decline with age, making it a candidate replacement peptide in geroscience studies<\/li>\n<li><strong>Kardiovaskul\u00e4rer und renaler Schutz<\/strong> \u2014 ischaemia-reperfusion injury, oxidative stress markers, mitochondrial dysfunction in cardiac and renal tissue study models<\/li>\n<li><strong>Bone health studies<\/strong> \u2014 Osteoblastendifferenzierung, Knochenmineraldichte, altersbedingte Osteoporosemodelle<\/li>\n<li><strong>Comparative mitochondrial peptide studies<\/strong> \u2014 Benchmarking gegen andere mitochondrial zielgerichtete Peptide wie <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a>. Siehe den Vergleichsabschnitt unten f\u00fcr eine methodische Gegen\u00fcberstellung.<\/li>\n<\/ul>\n<p>F\u00fcr einen breiteren Kontext, wo MOTS-c in das metabolische und Langlebigkeits-Peptid-Spektrum passt, siehe <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> als das kanonische kardiolipin-zielgerichtete mitochondriale Peptid, <a href=\"https:\/\/medsbase.com\/de\/epitalon\/\">Epitalon<\/a> for telomere\/longevity studies, and <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD+<\/a> for NAD-axis metabolic support. Browse the full <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">Peptid-Katalog<\/a> f\u00fcr verwandte Verbindungen. <\/p>\n<h2>Verf\u00fcgbare St\u00e4rken und Konzentrationen<\/h2>\n<p>MedsBase stocks MOTS-c in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial-St\u00e4rke<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typischer Anwendungsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Packungsgr\u00f6\u00dfen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mittlere Bulk-Fl\u00e4schchengr\u00f6\u00dfe, reduziertes Rekonstitutionsvolumen pro Dosis<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle protocols, longevity studies, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials yield greater per-vial dose flexibility and lower per-mg cost; the trade-off is that reconstituted solution must be used within 30 days, so multi-month protocols benefit from larger vials only when the per-week dose is correspondingly high. <\/p>\n<h2>Vergleich \u2014 MOTS-c vs SS-31 (Elamipretide)<\/h2>\n<p>MOTS-c und <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31<\/a> are the two most-cited mitochondrially-targeted peptides in current studies. They are mechanistically distinct and complementary, not redundant: MOTS-c is a signalling peptide that activates AMPK and nuclear-encoded adaptive programmes, while SS-31 is a structural peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. Users often pair them in mitochondrial-dysfunction models for this reason. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">SS-31 (Elamipretide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>L\u00e4nge<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 Aminos\u00e4uren<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4 Aminos\u00e4uren (Tetrapeptid)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Herkunft<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mitochondriale DNA-kodiert (12S rRNA-Gen)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Synthetisches Szeto-Schiller-Peptid<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Prim\u00e4rer Mechanismus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">AMPK-Aktivierung, nukle\u00e4re Genexpression<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cardiolipin-Bindung, ETC-Stabilisierung<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Zellul\u00e4res Ziel<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mitochondrium \u2192 Zytoplasma \u2192 Zellkern<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nur innere Mitochondrienmembran<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typische Dosis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\u201315 mg, 1\u20133x w\u00f6chentlich<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u20135 mg, t\u00e4glich<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Insulinsensitivit\u00e4t, k\u00f6rperliche Leistungsf\u00e4higkeit, Alterung<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kardiale Isch\u00e4mie, renale mitochondriale Dysfunktion<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Stacking<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequently co-administered with SS-31 in mitochondrial studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Wird h\u00e4ufig zusammen mit MOTS-c verabreicht<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides act on different layers of mitochondrial biology \u2014 MOTS-c regulates metabolic transcription, SS-31 stabilises membrane architecture \u2014 so they address non-overlapping studies questions. For metabolic\/insulin sensitivity, MOTS-c is the default first choice. For cardiac, renal, or ischaemia-reperfusion mitochondrial protection, SS-31 is the canonical comparator. <\/p>\n<h2>Lagerung und Rekonstitution<\/h2>\n<p><strong>Vor der Rekonstitution:<\/strong> Lagern Sie lyophilisierte Fl\u00e4schchen kurzzeitig als Arbeitsvorrat bei 2\u20138 \u00b0C im Originalbeh\u00e4lter. F\u00fcr unge\u00f6ffnete Langzeitlagerung bei \u221220 \u00b0C einfrieren. Lyophilisiertes MOTS-c ist unter K\u00fchlung bis zu 24 Monate und bei \u221220 \u00b0C bis zu 36 Monate stabil. Vermeiden Sie Gefrier-Tau-Zyklen des lyophilisierten Pulvers. <strong>Rekonstitutionsverfahren:<\/strong> Injizieren Sie bakterostatisches Wasser an der Seitenwand des Peptidfl\u00e4schchens entlang (nicht direkt auf den lyophilisierten Kuchen). Bei einem 10 mg-Fl\u00e4schchen ergibt 2,0 mL bakterostatisches Wasser eine Arbeitskonzentration von 5 mg\/mL \u2013 10 Striche auf einer U-100-Insulinspritze entsprechen 500 mcg. Behutsam schwenken \u2013 nicht <strong>nicht<\/strong> Sch\u00fctteln Sie \u2014 und lassen Sie 2\u20135 Minuten f\u00fcr die vollst\u00e4ndige Aufl\u00f6sung. Eine korrekt rekonstituierte L\u00f6sung sollte klar und farblos sein. <strong>gek\u00fchlt bei 2\u20138 \u00b0C lagern und innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren.<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because MOTS-c is typically dosed 1\u20133 times weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20133 weeks of dosing depending on the target dose and frequency. <\/p>\n<h2 id=\"faqs\">H\u00e4ufig gestellte Fragen<\/h2>\n<h3>What is MOTS-c used for in studies?<\/h3>\n<p>MOTS-c is used in studies investigating insulin sensitivity, type 2 diabetes models, exercise capacity, mitochondrial biogenesis, aging and longevity, cardiovascular ischaemia-reperfusion injury, renal mitochondrial dysfunction, and bone health. It is the most-cited mitochondrially-encoded signalling peptide in the published literature and serves as a benchmark for AMPK-axis interventions. MOTS-c is <strong>nicht<\/strong> FDA-approved and is supplied here strictly for clinical studies use only. <\/p>\n<h3>Wie unterscheidet sich MOTS-c von SS-31 (Elamipretide)?<\/h3>\n<p>MOTS-c is a 16-amino-acid signalling peptide encoded by mitochondrial DNA that activates AMPK and regulates nuclear gene expression. SS-31 is a 4-amino-acid synthetic Szeto-Schiller peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. The two address different layers of mitochondrial biology \u2014 MOTS-c at the metabolic-transcription level, SS-31 at the membrane-architecture level \u2014 and are frequently co-administered in mitochondrial-dysfunction studies. <\/p>\n<h3>What is the typical MOTS-c dose?<\/h3>\n<p>Ver\u00f6ffentlichte pr\u00e4klinische Protokolle verwenden typischerweise 5\u201315 mg pro Verabreichung in Nagetiermodellen, gegeben 1\u20133 Mal pro Woche \u00fcber Zyklen von 4\u201312 Wochen. Eine 10 mg Flasche, rekonstituiert mit 2,0 mL bakterienstatischem Wasser, ergibt 5 mg\/mL \u2013 10 Skalenteile auf einer U-100-Spritze entsprechen 500 mcg. <\/p>\n<h3>Ist MOTS-c von der FDA zugelassen?<\/h3>\n<p>No. MOTS-c is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>Wie sollte MOTS-c gelagert werden?<\/h3>\n<p>Lyophilisierte Fl\u00e4schchen: gek\u00fchlt bei 2\u20138 \u00b0C f\u00fcr kurzfristige Arbeitsbest\u00e4nde oder \u221220 \u00b0C f\u00fcr die Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituierte L\u00f6sung: gek\u00fchlt bei 2\u20138 \u00b0C, innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren \u2013 Gefrier-Auftau-Zyklen degradieren das Peptid. Immer vor direktem Licht sch\u00fctzen. <\/p>\n<h3>Wie rekonstituiere ich MOTS-c?<\/h3>\n<p>Befolgen Sie das oben beschriebene Rekonstitutionsverfahren. Geben Sie bakterienstatisches Wasser an der Seitenwand des Fl\u00e4schchens hinzu (nicht auf den lyophilisierten Kuchen), schwenken Sie vorsichtig und lassen Sie 2\u20135 Minuten zur vollst\u00e4ndigen Aufl\u00f6sung. Sch\u00fctteln Sie <strong>nicht<\/strong> Sch\u00fctteln Sie die Flasche. Eine korrekt rekonstituierte L\u00f6sung ist klar und farblos. Bei einer 10 mg Flasche + 2,0 mL L\u00f6sungsmittel betr\u00e4gt die Arbeitskonzentration 5 mg\/mL. <\/p>\n<h3>Welche St\u00e4rken f\u00fchrt MedsBase?<\/h3>\n<p>MedsBase carries MOTS-c in 10\u00a0mg, 20\u00a0mg, and 40\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Warum wird MOTS-c als \u201ctrainingsimitierendes\u201d Peptid bezeichnet?<\/h3>\n<p>The term derives from MOTS-c&#8217;s activation of AMPK and downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis \u2014 the same intracellular pathway responsible for many of the metabolic adaptations to exercise. In published studies, MOTS-c administration replicates several phenotypes of exercise training in sedentary animals: improved insulin sensitivity, increased treadmill endurance, and elevated PGC-1\u03b1 expression in skeletal muscle. The metaphor is widely used in geroscience and metabolic-syndrome literature. <\/p>\n<h3>Can MOTS-c and SS-31 be stacked in studies?<\/h3>\n<p>Yes. MOTS-c and SS-31 act on different layers of mitochondrial biology and are frequently co-administered in preclinical mitochondrial-dysfunction studies. MOTS-c regulates metabolic transcription via AMPK; SS-31 stabilises the inner-membrane lipid environment. Their mechanisms are complementary rather than overlapping, which makes the combination useful in study models of multi-axis mitochondrial decline. <\/p>\n<h3>Does MOTS-c cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses in rodent models, with no consistent off-target signals and good tolerability across 4\u201312 week dosing cycles. MOTS-c is structurally an endogenous human peptide, which reduces the risk of antibody-mediated reactions seen with engineered analogs. Long-term human safety data are not available because human trials are still in early stages. <\/p>\n<h3>Wie ist die Halbwertszeit von MOTS-c?<\/h3>\n<p>In preclinical studies, MOTS-c has an estimated plasma half-life of approximately 3\u20134 hours following subcutaneous administration. The relatively short systemic half-life is offset by intracellular accumulation and the peptide&#8217;s role as an intracellular signalling molecule rather than a circulating hormone \u2014 effects persist beyond the plasma clearance window in study models. <\/p>\n<h3>Warum nimmt endogenes MOTS-c mit dem Alter ab?<\/h3>\n<p>Published cohort data show roughly a 50% decline in human serum MOTS-c levels between young and aged adults. The mechanism is not fully understood but is thought to relate to age-associated mitochondrial DNA mutations, declining mitochondrial transcription, and reduced biosynthesis of mitochondrially-encoded peptides in general. The age-related decline is one reason MOTS-c has attracted strong interest in longevity and geroscience studies. <\/p>\n<h3>How long does MOTS-c take to show effects in preclinical studies?<\/h3>\n<p>Akute Effekte auf AMPK-Phosphorylierung und Glukoseaufnahme sind innerhalb von Stunden nach Gabe nachweisbar. Insulinsensitivit\u00e4ts- und K\u00f6rperzusammensetzungseffekte in Nagetiermodellen mit fettreicher Di\u00e4t werden typischerweise nach 2\u20134 Wochen regelm\u00e4\u00dfiger Dosierung statistisch signifikant. Verbesserungen der Belastungskapazit\u00e4t (Laufbandausdauer, VO<sub>2<\/sub>max surrogates) accrue over 4\u20138 weeks of continuous dosing. <\/p>\n<h3>Kann ich MOTS-c f\u00fcr den internationalen Versand bestellen?<\/h3>\n<p>Ja. MedsBase versendet MOTS-c weltweit \u00fcber unser spezielles Peptid-Versandnetzwerk. Bestellungen, die nur Peptide enthalten, qualifizieren sich f\u00fcr unseren eigenst\u00e4ndigen Peptid-Versandservice. Alle Bestellungen werden in temperaturkontrollierter Verpackung mit vollst\u00e4ndiger Sendungsverfolgung versandt und sind abgedeckt durch unser <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Mitochondrial, and Longevity Studies<\/h2>\n<ul>\n<li><a href=\"\/de\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Cardiolipin-bindendes mitochondriales Tetrapeptid \u2014 kanonischer Stabilisator der inneren Membran<\/li>\n<li><a href=\"\/de\/nad\/\"><strong>NAD+<\/strong><\/a> \u2014 Nicotinamide adenine dinucleotide \u2014 sirtuin\/longevity-axis metabolic support<\/li>\n<li><a href=\"\/de\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 telomerase activation and longevity studies<\/li>\n<li><a href=\"\/de\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Long-acting GLP-1 agonist \u2014 glycaemic and body-weight studies<\/li>\n<li><a href=\"\/de\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Weiterf\u00fchrende Literatur<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Vergleichen Sie mitochondriell zielgerichtete Peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Entdecken Sie die breitere <a href=\"https:\/\/medsbase.com\/de\/peptides\/\"><strong>Peptid-Katalog<\/strong><\/a> f\u00fcr mitochondriale und metabolische Peptide, einschlie\u00dflich <a href=\"https:\/\/medsbase.com\/de\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-targeted membrane studies, <a href=\"https:\/\/medsbase.com\/de\/nad\/\">NAD+<\/a> for sirtuin-axis longevity studies, and <a href=\"https:\/\/medsbase.com\/de\/epitalon\/\">Epitalon<\/a> for telomere-axis longevity studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Mitochondrial kodiertes Signalisierungspeptid<br \/>\n\u2705 Aktiviert den AMPK-Stoffwechselweg<br \/>\n\u2705 Unterst\u00fctzt die Insulinsensitivit\u00e4t<br \/>\n\u2705 Trainingsmimetikum in pr\u00e4klinischen Modellen<br \/>\n\u2705 Longevity &amp; geroscience compound<\/p>\n<p><strong>MOTS-c<\/strong> enth\u00e4lt synthetische Peptidverbindung.<\/p>","protected":false},"featured_media":70967,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6272,5441],"class_list":["post-70664","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mots-c","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product\/70664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/comments?post=70664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media\/70967"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media?parent=70664"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_brand?post=70664"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_cat?post=70664"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_tag?post=70664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}